Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Withdrawal of benzodiazepines in primary care usually requires careful tapering of the dosage

    This is a preview of subscription content, log in to check access.

    Table I
    Table II

    References

    1. 1.

      Lader M, Tylee A, Donoghue J. Withdrawing benzodiazepines in primary care. CNS Drugs 2009; 23(1): 19–34

    2. 2.

      O’Brien CP. Benzodiazepine use, abuse and dependence. J Clin Psychiatry 2005; 66Suppl. 2: 28–33

    3. 3.

      Taylor S, McCracken CF, Wilson KC, et al. Extent and appropriateness of benzodiazepine use: results from an elderly urban community. Br J Psychiatry 1998; 173: 433–8

    4. 4.

      Lader M. Benzodiazepines: a risk-benefit profile. CNS Drugs 1994; 1: 377–87

    5. 5.

      Kripke DF, Klauber MR, Wingard DL, et al. Mortality hazard associated with prescription of hypnotics. Biol Psychiatry 1998; 43(9): 687–93

    6. 6.

      Siriwardena AN, Qureshi Z, Gibson S, et al. GP’s attitudes to benzodiazepine and “z-drug” prescribing: a barrier to implementation of evidence and guidance on hypnotics. Br J Gen Pract 2006; 56(533): 964–7

    7. 7.

      National Institute for Clinical Excellence. Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia. London: National Institute for Clinical Excellence, 2004 Apr: Technology appraisal no. 77

    8. 8.

      Estivill E, Bove A, Garcia-Borreguero D, et al. Consensus on drug treatment, definition and diagnosis for insomnia. Clin Drug Invest 2003; 23(6): 351–85

    9. 9.

      British Medical Association and the Royal Pharmaceutical Society of Great Britain. British national formulary. No. 57. London: BMJ Publishing Group Ltd and RPS Publishing, 2009 Mar

    10. 10.

      Hughes LM, Holden JD, Tree AM. Audit as a method of reducing benzodiazepine prescribing in general practice. J Clin Eff 1997; 2: 79–82

    11. 11.

      Bashir K, King M, Ashworth M. Controlled evaluation of brief intervention by general practitioners to reduce chronic use of benzodiazepines. Br J Gen Pract 1994; 44(386): 408–12

    12. 12.

      Towle I, Adams J. A novel, pharmacist-led strategy to reduce the prescribing of benzodiazepines in Paisley. Pharm J 2006; 276: 136–8

    13. 13.

      Cormack MA, Sweeney KG, Hughes J, et al. Evaluation of an easy cost-effective strategy for cutting benzodiazepine use in general practice. Br J Gen Pract 1994; 44(378): 5–8

    14. 14.

      Gorgels WJM, Oude Voshar RC, Mol AJ, et al. Predictors of discontinuation of benzodiazepine prescription after sending a letter to long-term benzodiazepine users in family practice. Fam Pract 2006; 23(1): 65–72

    15. 15.

      Baker R, Farooqi A, Tait C, et al. Randomised controlled trial of reminders to enhance the impact of audit in general practice on management of patients who use benzodiazepines. Qual Health Care 1997; 6(1): 14–8

    16. 16.

      Dollman WB, LeBlanc VT, Stevens LO, et al. Achieving a sustained reduction in benzodiazepine use through implementation of an area-wide multi-strategic approach. J Clin Pharm Ther 2005; 30(5): 425–32

    17. 17.

      Jørgensen VRK. An approach to reduce benzodiazepine and cyclopyrrolone use in general practice: a study based on a Danish population. CNS Drugs 2007; 21(11): 947–55

    18. 18.

      Denis C, Fatseas M, Lavie E, et al. Pharmacological interventions for benzodiazepine mono-dependence in outpatient settings. Cochrane Database Syst Rev 2006; (3): CD005194

    19. 19.

      Strom Jr JG, Kalu AU. Formulation and stability of diazepam suspension compounded from tablets. Am J Hosp Pharm 1986 Jun; 43(6): 1489–91

    20. 20.

      Sips JHM, Pessers JW. Quit without suffering [in Dutch; online]. Available from URL: http://www.knmp.nl/download-bestanden/fpz-prijs/fpz-prijs-2009/stoppen-zonder-lijden/projectbeschrijving-stoppen-zonder-lijden.pdf [Accesssed 2009 Jun 10]

    21. 21.

      Saxon L, Hjemdahl P, Hiltunen AJ, et al. Effects of flumazenil in the treatment of benzodiazepine withdrawal: a double-blind pilot study. Psychopharmacol 1997; 131(2): 153–60

    22. 22.

      Gerra G, Zaimovic A, Giusti F, et al. Intravenous flumazenil versus oxazepam tapering in the treatment of benzodiazepine withdrawal: a randomized placebo-controlled study. Addict Biol 2002; 7(4): 385–95

    23. 23.

      Nutt DJ, Glue P, Lawson C, et al. Flumazenil provocation of panic attacks. Arch Gen Psychiatry 1990; 47(10): 9176–25

    24. 24.

      Mintzer MZ, Stoller KB, Griffiths RR. A controlled study of flumazenil-precipitated withdrawal in low-dose benzodiazepoine users. Psychopharmacology 1999; 147(2): 200–9

    25. 25.

      Bernik MA, Gorenstein C, Veira Filho AHG. Stressful reactions and panic attacks induced by flumazenil in chronic benzodiazepine users. J Psychopharmacol 1998; 12(2): 146–50

    26. 26.

      Spiegel DA. Psychological strategies for discontinuing benzodiazepine treatment. J Clin Psychopharmacol 1999; 19(6 Suppl. 2): 17–22S

    27. 27.

      Gosselin P, Ladouceur R, Morin CM, et al. Benzodiazepine discontinuation among adults with GAD: a randomized trial of cognitive-behavioral therapy. J Consult Clin Psychol 2006; 74(5): 908–19

    28. 28.

      Oude Voshaar RC, Gorgels WJ, Mol AJ, et al. Tapering off long-term benzodiazepine use with or without group cognitive-behavioural therapy: three-condition, randomised controlled trial. Br J Psychiatry 2003; 182: 498–504

    29. 29.

      Olajide D, Lader M. Depression following withdrawal from long-term benzodiazepine use: a report of four cases. Psychol Med 1984; 14(4): 937–40

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Withdrawal of benzodiazepines in primary care usually requires careful tapering of the dosage. Drugs Ther. Perspect 25, 23–26 (2009). https://doi.org/10.2165/0042310-200925090-00007

    Download citation